Proving Economic Value

Public and private healthcare systems are under immense pressure to increase access and quality of care while constraining cost. From reform in the US and national budget crises in Europe, to shifting demographics in Japan and demand for universal care in the up-and-coming markets of Asia and Latin America, global economic forces are pushing drug costs into the spotlight. No longer do incremental safety and efficacy claims justify a higher price. Even in areas of high unmet need—areas like oncology and autoimmune diseases—payers are demanding more proof of value. They want to understand how new medicines affect their economics, and the resulting mandate for pharma is clear: Prove it.

The tactics pharma has employed over the past decade simply will not prevail in the next one. But we believe the industry is up for the challenge—and Oliver Wyman can help. 

Oliver Wyman can prepare pharmaceutical companies to thrive in this new environment by:

• Understanding the impact of new drugs on the economics of Payers and Providers, leveraging robust data that demystifies elements of healthcare cost across specific diseases and patient segments.
• Developing strategies for proving the value of new medicines, integrating clinical and commercial strategies with health economics to ensure optimal product positioning at launch.
• Managing the evidence generation lifecycle, designing programs to demonstrate the long-term value of products to the right stakeholders at the right time, from product launch through loss of exclusivity and beyond.
• Aligning pharmaceutical portfolios for future healthcare system realities, assessing the strength of the portfolio from a market access perspective and optimizing evidence generation investments across assets.
• Redesigning market access organizations for the future, creating winning teams and operating principles that blend clinical, medical, and commercial expertise to prove the value of therapeutic innovation.